The Indiana Applied Research Enterprise already has received support from John Lechleiter, CEO of Indianapolis-based Eli Lilly and Co., as a place for collaboration between academic and industrial scientists.
Early-stage venture capital has been harder and harder to come by for life sciences companies in recent years, but two Indianapolis investors are working to raise sizable funds to help fill the gap.
Community Health Network thinks it can help patients, engage doctors and maybe even make some money by trying to turn ideas within its organization into commercial products, service and companies.
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a “world-class” research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
Even though the potential payoff for health care innovation is less certain these days, the business case for new ways to produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural innovation.
Research and development comes under pressure in an age of austerity.
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
Purdue University’s new Innovation and Commercialization Center is supposed to be a one-stop shop for professors to get help developing their research into products and for outside investors to find out what research is taking place there.
Licensed practical nurse Nic Davis invented a device to kill and prevent the introduction of microorganisms that collect at catheter ports.
The Indiana University School of Medicine has licensed a pediatric psychiatrist’s patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
TechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
Ball State University is conducting a nationwide search for a president to lead a not-for-profit it launched to boost the commercialization of the university’s intellectual property.
Over the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center, launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life and Health Sciences Quadrangle next to Discovery Park.
Mark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
Indiana University had a license or two to print money from the commercialization of its technology over the last year—and did it ever. While Purdue University didn’t collect as much in royalties from commercialization, it pulled down record levels of research grants.
A firm that may have developed a breakthrough yeast for ethanol production has landed new investment and high-octane board
members. Two-year-old Xylogenics Inc. also says it plans to license its first bioengineered yeast later this year.
Having invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
A Purdue University-based company has reached a deal giving Chinese and Danish firms access to a patented product that makes
it easier to turn wood chips, grasses and other agricultural wastes into ethanol.
